Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Apr 7;221(9):1407-1415.
doi: 10.1093/infdis/jiz281.

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS)

Affiliations
Clinical Trial

Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS)

Rajesh T Gandhi et al. J Infect Dis. .

Abstract

Background: Short-term (48-week) results of the OPTIONS trial showed that nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from salvage therapy as long as the regimen has a cumulative activity of >2 active antiretroviral medications. The long-term durability of this approach and outcomes in persons who have more-extensive HIV-1 drug resistance are uncertain.

Methods: Participants with virologic failure and anticipated antiretroviral susceptibility received an optimized regimen and were randomized to omit or add NRTIs. A separate group with more resistance (cumulative activity ≤2 active agents) received an optimized regimen including NRTIs.

Results: At week 96, among 360 participants randomized to omit or add NRTIs, 70% and 65% had HIV-1 RNA <200 copies/mL, respectively. Virologic failure was uncommon after week 48. Younger age and starting fewer new antiretroviral medications were associated with higher odds of virologic failure. In the highly resistant group, 53% had HIV-1 RNA <200 copies/mL at week 96.

Conclusions: HIV-1 salvage therapy can safely omit NRTIs without compromising efficacy or durability of response as long as the new regimen has a cumulative activity of >2 active drugs. Younger people and those receiving fewer new antiretrovirals require careful monitoring. Even among individuals with more-extensive resistance, most achieve virologic suppression.

Clinical trials registration: NCT00537394.

Keywords: HIV-1; antiretroviral therapy; drug resistance; randomized controlled trial; salvage therapy; treatment-experienced participants.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant disposition. Abbreviation: NRTI, nucleoside reverse transcriptase inhibitor.
Figure 2.
Figure 2.
Cumulative probability of virologic failure over time by treatment group. Abbreviation: NRTI, nucleoside reverse transcriptase inhibitor.
Figure 3.
Figure 3.
Mean quality of life score and change in quality of life score over time by treatment group. Quality of life was assessed using the general health score, which uses a visual analog scale that ranges from 0 (worst possible health) to 100 (perfect health). Abbreviation: NRTI, nucleoside reverse transcriptase inhibitor.

Comment in

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV Department of Health and Human Services; https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/v.... Accessed 24 December 2017.
    1. Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. ; A5241 Study Team HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial. Ann Intern Med 2015; 163:908–17. - PMC - PubMed
    1. Tashima KT, Mollan KR, Na L, et al. . Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials 2015; 16:147–56. - PMC - PubMed
    1. Stanford University. HIV drug resistance database https://hivdb.stanford.edu/. Accessed 5 June 2019.
    1. Tungsiripat M, Kitch D, Glesby MJ, et al. . A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24:1781–4. - PMC - PubMed

Publication types

Associated data